Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7 days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and cognition function tests.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Enrollment
36
Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
Subjects will receive Simvastatin 10 mg tablets orally.
GSK Investigational Site
Berlin, Germany
-AE, Lab values and cardiovascular monitoring after the SD and 14 days RD period (15 days)
Time frame: after the SD and 14 days RD period (15 days)
- SB649868 levels on days -7, 1, 4, 7 and 14 (pre-dose and post-dose)
Time frame: on days -7, 1, 4, 7 and 14 (pre-dose and post-dose)
- Simvastatine and Beta-idroxy-simvastatine levels on days -10,1,4,7 and 15
Time frame: on days -10,1,4,7 and 15
Cognitive functions, sleep profile and appetite assessment on days -7, 7 and 14.
Time frame: on days -7, 7 and 14.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.